The use of nucleic acid derived aptamers has rapidly expanded since the introduction of SELEX in 1990. Nucleic acid aptamers have demonstrated their ability to target a broad range of molecules in ways that rival antibodies. but advances have been very uneven for different biochemical classes of targets. and clinical applications have been slow to emerge. https://rbdoutlet.shop/product-category/big-kids-shoes/